编辑推荐——自体血管旁路移植物闭塞全因患者的血管腔内治疗与外科治疗对比:多中心ENSUPRO研究
该多中心回顾性队列研究纳入2014年1月至2021年12月18个中心260例症状性人工血管旁路移植物(PBG)闭塞患者,比较血管腔内、杂交与开放手术等策略。中位随访1.4年,四组无截肢生存率分别为95.5%、76.4%、45.5%和37.1%(p=.007);血管腔内治疗与更高的无截肢生存率和Rutherford分级改善率及更低的PBG再闭塞率和靶病变血运重建率相关,全因死亡率组间相当。
要点
- 血管腔内治疗与更高的无截肢生存率和Rutherford分级改善率相关。
- 血管腔内治疗与更低的PBG再闭塞率和靶病变血运重建率相关。
- 全因死亡率在各治疗组间相当(p=.21)。
核心结论
- 在PBG闭塞患者中,血管腔内治疗与更高的无截肢生存率和Rutherford分级改善率以及更低的PBG再闭塞率和靶病变血运重建率相关。
研究设计与样本
- 多中心回顾性队列研究,纳入2014年1月至2021年12月来自18个中心的症状性PBG闭塞患者260例。
- 比较四种治疗策略:开通自体血管、对失败PBG行血管腔内治疗、杂交治疗和开放手术。
- 主要结局为无截肢生存率(至大截肢和/或死亡时间),次要结局包括全因死亡、大截肢、PBG再闭塞、靶病变血运重建和随访期间Rutherford分级改善。
主要发现
- 260例PBG闭塞患者中,108例(41.5%)接受血管腔内治疗(其中24例[22.2%]开通自体血管,84例[77.7%]重新开通PBG),57例(21.9%)接受杂交血运重建,58例(22.3%)接受手术,27例(10.4%)保守治疗,10例(3.8%)接受系统性溶栓。
- 中位随访1.4(0.6-3.0)年,第1至4组无截肢生存率分别为95.5%、76.4%、45.5%和37.1%(p=.007)。
- 年龄较大和非血管腔内治疗是无截肢生存率不良的独立预测因素(HR 1.05和1.70;两者p<.01)。
- 血管腔内治疗与大截肢率较低(p=.04)、PBG再闭塞率较低(p<.001)、靶病变血运重建率较低(p=.037)和Rutherford分级改善率较高(p<.001)相关,而全因死亡率在各治疗组间相当(p=.21)。
临床怎么用
- 作者认为,对于PBG闭塞患者,血管腔内治疗与更高的无截肢生存率和Rutherford分级改善率以及更低的PBG再闭塞率和靶病变血运重建率相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Bypass surgery plays a key role in complex lower limb lesions. However, there is a lack of evidence regarding the management of symptomatic prosthetic bypass graft (PBG) occlusion. This study aimed to report outcomes following open, hybrid, or endovascular management of patients presenting with symptomatic PBG occlusion. METHODS: A multicentre, retrospective cohort study was conducted, including patients presenting with PBG occlusion between January 2014 and December 2021 from 18 centres. It assessed the comparative value of treatment strategies, including (1) recanalisation of native vessels, (2) endovascular treatment of the failed PBG, (3) hybrid treatment, and (4) open surgery. The primary outcome measure was amputation free survival (AFS, time to major amputation and or death), whereas all cause mortality, major amputation, PBG re-occlusion, target lesion revascularisation (TLR), and Rutherford category (RC) improvement during follow up were considered as secondary endpoints. RESULTS: Of 260 patients with occluded PBGs, 108 (41.5%) were treated endovascularly (24 [22.2%] by recanalisation of native vessels and 84 [77.7%] by PBG re-opening), 57 (21.9%) underwent hybrid revascularisation, and 58 (22.3%) had surgery. In addition, 27 (10.4%) were treated conservatively and 10 (3.8%) received systemic thrombolysis. With a median follow up of 1.4 (0.6 - 3.0) years, AFS was 95.5%, 76.4%, 45.5%, and 37.1%, respectively in Groups 1 - 4 (p = .007). Older age and non-endovascular treatment (HR 1.05 and 1.70; p < .01 for both) were independent predictors of poor AFS. Endovascular treatment was associated with lower rates of major amputation (p = .04), PBG re-occlusion (p < .001), and TLR (p = .037), and higher RC improvements (p < .001), whereas all cause mortality was comparable between treatment groups (p = .21). CONCLUSION: Endovascular treatment is associated with higher rates of AFS and RC improvement and lower rates of PBG re-occlusion and TLR in patients with PBG occlusion.
引用
- Korosoglou G, Torsello G, Saratzis A, et al. Editor's Choice - Endovascular Versus Surgical Treatment for All Comer Patients With Prosthetic Bypass Graft Occlusion: The Multicentre ENSUPRO Study. Eur J Vasc Endovasc Surg. 2023. PMID: 37543355. doi:10.1016/j.ejvs.2023.07.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。